Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review

Bibliography

• Chiesa A, Leucci V, Serretti A, et al. Antipsychotics and sexual dysfunction: epidemiology, mechanisms and management. Clin Neuropsychia 2013;10(1):31-6
   Google Scholar
• Kalkavoura CS, Michopoulos I, Arvanitakis P, et al. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol 2013;21(4):332-41
   PubMed Web of Science ®Google Scholar
• Rosenberg KP, Bleiberg KL, Koscis J, et al. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003;29(4):289-96
   PubMed Web of Science ®Google Scholar
• Montejo AL, Riesgo Y, Luque J, et al. Observational, open-label, prospective multicenter study of sexual function in patients starting treatment with aripiprazole. Actas Esp Psiquiatr 2010;38(1):13-21
   PubMed Web of Science ®Google Scholar
• Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive literature review. CNS Drugs 2014, doi: 10.1007/s40263-014-0157-3
   PubMed Web of Science ®Google Scholar
• Kelly DL, Wehring HJ, Earl AK, et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry 2013; Published online 22 August 2013, doi: 10.1186/1471-244X-13-214
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011;26(3):130-40
   PubMedGoogle Scholar
• Serretti A, Chiesa A. Sexual side effects of pharmacological treatment of psychiatric diseases. Clin Pharmacol Ther 2011;89(1):142-7
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol2009;19(8)542-50
   PubMed Web of Science ®Google Scholar
• Kropp S, Ziegenbein M, Grohmann R, et al. Galactorrhea due to psychotropic drugs. Pharmacopsychiatry 2004;37(Suppl 1):S84-8
   PubMedGoogle Scholar
• Mortimer A, Martin S, Lôo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004;19(2):63-9
   PubMed Web of Science ®Google Scholar
• Malik P, Kemmler G, Hummer M, et al. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol 2011;31(3):274-80
   PubMed Web of Science ®Google Scholar
• Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008;23(3):201-9
   PubMed Web of Science ®Google Scholar
• Hanssens L, L'Italien G, Loze JY, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008;8:95
   PubMed Web of Science ®Google Scholar
• Ziadi Trives M, Bonete Llácer JM, García Escudero MA, Martínez Pastor CJ. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol 2013;33(4):538-41
   PubMed Web of Science ®Google Scholar
• Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008;22(3):244-53
   PubMed Web of Science ®Google Scholar
• Park YW, Kim Y, Lee JH. Antipsychotic-induced sexual dysfunction and its management. World J Mens Health 2012;30(3):153-9
   PubMedGoogle Scholar
• Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev 2012;6:CD008296
   Google Scholar
• Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol 2010;25(6):334-41
   PubMed Web of Science ®Google Scholar
• Montalvo I, Ortega L, López X, et al. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Int Clin Psychopharmacol 2013;28(1):46-9
   PubMed Web of Science ®Google Scholar
• Montejo González AL, Rico-Villademoros F, Tafalla M, et al. A 6 month prospective observational studyon the effects of quetiapine on sexual functioning. J Clin Psychopharmacol 2005;25(6):533-8
   PubMed Web of Science ®Google Scholar
• van Bruggen M, van Amelsvoort T, Wouters L, et al. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology 2009;34(7):989-95
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Nakonezny PA, Rush AJ. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. Psychiatry Res 2008;159(1-2):115-20
   PubMed Web of Science ®Google Scholar
• Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006;31(3):340-6
   PubMed Web of Science ®Google Scholar
• Bobes J, Garc A-Portilla MP, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29(2):125-47
   PubMed Web of Science ®Google Scholar
• Knegtering R, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004;24(1):56-61
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Nakonezny PA, Bettcher BM, et al. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res 2006;86(1-3):244-50
   PubMed Web of Science ®Google Scholar
• Konarzewska B, Wołczyński S, Szulc A, et al. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009;34(1):129-39
   PubMed Web of Science ®Google Scholar
• Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158(5):765-74
   PubMed Web of Science ®Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, et al. Emerging treatments in the management of schizophrenia - focus on sertindole. Drug Des Devel Ther 2010;4:187-201
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;(2):CD006752
   Google Scholar
• Hale A, Azorin JM, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatry Clin Pract 2000;4:55-62
   PubMed Web of Science ®Google Scholar
• Montejo AL, Rico-Villademoros F, Spanish Working Group for the Study of Psychotropic Related Sexual Dysfunction. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study. J Clin Psychopharmacol 2008;28(5):568-70
   PubMed Web of Science ®Google Scholar
• Nebhinani N, Grover S, Avasthi A. Sexual dysfunction in male subjects receiving trifluoperazine, risperidone, or olanzapine: rates vary with assessment questionnaire. Prim Care Companion CNS Disord 2012;14(2):PCC.11m01199
   Google Scholar
• Lambert M, Haro JM, Novick D, et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 2005;111(3):232-43
   PubMed Web of Science ®Google Scholar
• Mahmoud A, Hayhurst KP, Drake RJ, et al. Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial. Schizophr Res Treatment 2011;2011:596898
   Google Scholar
• Mahmoud A, Hayhurst KP, Drake RJ, et al. Sexual function of patients with schizophrenia receiving first-generation (FGA) or second-generation antipsychotic (SGA) treatment. Int J Psychiatry Clin Pract 2012;16(2):148-52
   PubMed Web of Science ®Google Scholar
• Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol 2013;6(1):61-91
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Iloperidone for the treatment of schizophrenia: an updated clinical review. Clin Schizophr Relat Psychoses 2012;6(1):34-44
   PubMedGoogle Scholar
• Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol 2013;6(1):61-91
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Wong R. Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia. Clin Schizophr Relat Psychoses 2012;5(4):217-20
   PubMedGoogle Scholar
• Szegedi A, Verweij P, van Duijnhoven W, et al. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry 2012;73(12):1533-40
   PubMed Web of Science ®Google Scholar
• Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother 2012;13(11):1599-613
   PubMed Web of Science ®Google Scholar
• Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 2013;27(11):879-911
   PubMed Web of Science ®Google Scholar
• Dainippon Sumitomo Pharma. DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone. News release. 2012. Available from: http://www.ds-pharma.com/news/2012/20121025.html [Last accessed 18 November 2013]
   Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62
   PubMed Web of Science ®Google Scholar
• Wang SM, Han C, Lee SJ, et al. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol 2013;36(6):223-38
   PubMed Web of Science ®Google Scholar
• SAPHRIS® (asenapine). Highlights of prescribing information. U.S. Food and Drug Administration. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022117s012lbl.pdf [Last accessed 12 November 2013]
   Google Scholar
• Gonzalez JM, Thompson PM, Moore TA. Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. Patient Prefer Adherence 2011;5:333-41
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Kalali AH, Mattingly GW, et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr 2013;18(1):43-54
   PubMed Web of Science ®Google Scholar
• Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2010;64(6):707-18
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-8
   PubMed Web of Science ®Google Scholar
• FANAPT® (iloperidone). Highlights of prescribing information. U.S. Food and Drug Administration. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022192s007lbl.pdf [Last accessed 12 November 2013]
   Google Scholar
• Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry 2011;72(Suppl 1):19-23
   PubMedGoogle Scholar
• Arif SA, Mitchell MM. Iloperidone: a new drug for the treatment of schizophrenia. Am J Health Syst Pharm 2011;68(4):301-8
   PubMed Web of Science ®Google Scholar
• LATUDA® (lurasidone). Highlights of prescribing information. U.S. Food and Drug Administration. 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200603s000lbl.pdf [Last accessed 12 November 2013]
   Google Scholar
• Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl) 2013;225(3):519-30
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry 2013;74(2):170-9
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res 2013;47(5):670-7
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 2013;145(1-3):101-9
   PubMed Web of Science ®Google Scholar
• Knegtering H, van den Bosch R, Castelein S, et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology 2008;33(6):711-17
   PubMed Web of Science ®Google Scholar
• Westheide J, Cvetanovska G, Albrecht C, et al. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med 2008;5(12):2816-26
   PubMed Web of Science ®Google Scholar
• Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005;66(6):761-7
   PubMed Web of Science ®Google Scholar
• Rettenbacher MA, Hofer A, Ebenbichler C, et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol 2010;30(6):711-15
   PubMed Web of Science ®Google Scholar
• Dickson RA, Dalby JT, Williams R, et al. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995;152(7):1102-3
   PubMed Web of Science ®Google Scholar
• Liu-Seifert H, Kinon BJ, Tennant CJ, et al. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat 2009;5:47-54
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28(Suppl 2):55-68
   PubMed Web of Science ®Google Scholar
• Nakonezny PA, Byerly MJ, Rush AJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther 2007;33(3):203-16
   PubMed Web of Science ®Google Scholar
• Ali S, Miller KK, Freudenreich O. Management of psychosis associated with a prolactinoma: case report and review of the literature. Psychosomatics 2010;51(5):370-6
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Fujii A, Sugawara N, et al. No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Hum Psychopharmacol 2012;27(1):82-9
   PubMed Web of Science ®Google Scholar
• Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19(1):57-61
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15(1):111-17
   PubMed Web of Science ®Google Scholar
• Berry S, Martinez A, Myers J, et al. Serum prolactin in schizophrenia. Poster presented at the 7th World Congress of Biological Psychiatry; 1 – 6 July 2001; Berlin, Germany
   Google Scholar
• Kikuchi T, Iwamoto K, Sasada K, et al. Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2012;37(1):26-32
   PubMed Web of Science ®Google Scholar
• Eberhard J, Lindström E, Holstad M, et al. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 2007;115(4):268-76
   PubMed Web of Science ®Google Scholar
• Howes OD, Wheeler MJ, Pilowsky LS, et al. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry 2007;68(3):361-7
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E. A new atypical antipsychotic: quetiapine-induced sexual dysfunctions. Int J Impot Res 2005;17(2):201-3
   PubMed Web of Science ®Google Scholar
• Lundberg PO, Hulter B. Sexual dysfunction in patients with hypothalamo-pituitary disorders. Exp Clin Endocrinol 1991;98(2):81-8
   PubMedGoogle Scholar
• Canuso CM, Goldstein JM, Wojcik J, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 2002;111(1):11-20
   PubMed Web of Science ®Google Scholar
• Smith SM. The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol 2008;22(2 Suppl):63-9
   PubMedGoogle Scholar
• Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008;22(2 Suppl):98-103
   PubMedGoogle Scholar
• Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 2008;22(2 Suppl):90-7
   PubMedGoogle Scholar
• Peluso MJ, Lewis SW, Barnes TR, et al. Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1). Schizophr Res 2013;144(1-3):80-6
   PubMed Web of Science ®Google Scholar
• Nunes LV, Moreira HC, Razzouk D, et al. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther 2012;38(3):281-301
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Des Devel Ther 2012;6:107-15
   PubMed Web of Science ®Google Scholar
• Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol 2012;26(5 Suppl):42-51
   PubMedGoogle Scholar
• Reis Marques T, Smith S, Bonaccorso S, et al. Sexual dysfunction in people with prodromal or first-episode psychosis. Br J Psychiatry 2012;201:131-6
   PubMed Web of Science ®Google Scholar
• Zemishlany Z, Weizman A. The impact of mental illness on sexual dysfunction. Adv Psychosom Med 2008;29:89-106
   PubMed Web of Science ®Google Scholar
• Peuskens J, Sienaert P, De Hert M. Sexual dysfunction: the unspoken side effect of antipsychotics. Eur Psychiatry 1998;13(Suppl 1):23s-30s
   Google Scholar
• Zhang XR, Zhang ZJ, Zhu RX, et al. Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics 2011;12(8):1127-36
   PubMed Web of Science ®Google Scholar
• Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 2010;24(1):111-20
   PubMed Web of Science ®Google Scholar
• Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67(Suppl 6):33-7
   PubMed Web of Science ®Google Scholar
• Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63(4):357-66
   PubMed Web of Science ®Google Scholar
• Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(Suppl 3):10-21
   PubMed Web of Science ®Google Scholar
• Kim S, Park YM. Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study. PLoS One 2013;8(12):e82749
   PubMedGoogle Scholar
• Schmidt HM, Hagen M, Kriston L, et al. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev 2012;11:CD003546
   PubMedGoogle Scholar
• Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334-49
   PubMed Web of Science ®Google Scholar
• Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005;80(8):1050-7
   PubMed Web of Science ®Google Scholar
• Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 2008;18(Suppl 2):S108-14
   PubMed Web of Science ®Google Scholar
• Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ 2003;169(6):575-81
   PubMed Web of Science ®Google Scholar
• Arafah BM, Nekl KE, Gold RS, et al. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab 1995;80(12):3507-12
   PubMed Web of Science ®Google Scholar
• Walters J, Jones I. Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol 2008;22(2 Suppl):82-9
   PubMedGoogle Scholar
• Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem 2010;47(Pt 4):292-300
   PubMed Web of Science ®Google Scholar
• Ajmal A, Joffe H, Nachtigall LB. Psychotropic-Induced Hyperprolactinemia: a Clinical Review. Psychosomatics 2014;55(1):29-36
   PubMed Web of Science ®Google Scholar
• De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10(2):138-51
   PubMed Web of Science ®Google Scholar
• Byerly M, Suppes T, Tran QV, et al. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007;27(6):639-61
   PubMed Web of Science ®Google Scholar
• Knegtering R, Castelein S, Bruggeman R. Vaak seksuele functiestoornissen door antipsychotica, vooral bij prolactineverhoging. Resultaten van een aantal vergelijkende onderzoeken. Tijdschrift Voor Seksuologie 2004;28:140-6
   Google Scholar
• Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291-314
   PubMed Web of Science ®Google Scholar
• Costa AM, Lima MS, Mari Jde J. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J 2006;124(5):291-7
   PubMedGoogle Scholar
• Howes O, Smith S. Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessed. BMJ 2002;324(7348):1278
   PubMed Web of Science ®Google Scholar
• Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 2008;69(Suppl 1):32-44
   PubMedGoogle Scholar
• Goffin V, Touraine P, Culler MD, et al. Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab 2006;2(10):571-81
   PubMedGoogle Scholar
• La Torre A, Conca A, Duffy D, et al. Sexual Dysfunction Related to Psychotropic Drugs: a Critical Review Part II: antipsychotics. Pharmacopsychiatry 2013;46(6):201-8
   PubMed Web of Science ®Google Scholar
• Yuan HN, Wang CY, Sze CW, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol 2008;28(3):264-370
   PubMed Web of Science ®Google Scholar
• CYCLOSET® (bromocriptine mesylate). Highlights of prescribing information. U.S. Food and Drug Administration. 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020866lbl.pdf [ Last accessed 12 November 2013]
   Google Scholar
• Baeza Pertegaz I, Goikolea Alberdi JM, Parellada Rodón E. Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms? J Psychiatry Neurosci 2002;27(1):54
   PubMed Web of Science ®Google Scholar
• Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004;65(2):187-90
   PubMed Web of Science ®Google Scholar
• Chang SC, Chen CH, Lu ML. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry 2008;30(4):378-80
   PubMed Web of Science ®Google Scholar
• De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves : meta-analysis of observational studies. Herz 2013;38(8):868-80
   PubMed Web of Science ®Google Scholar
• Bogazzi F, Manetti L, Raffaelli V, et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 2008;31(12):1119-23
   PubMed Web of Science ®Google Scholar
• Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord 2009;24(1):129-33
   PubMed Web of Science ®Google Scholar
• Wang D, Wong HK, Zhang L, et al. Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia. Prog Neuropsychopharmacol Biol Psychiatry 2012;39(2):332-8
   PubMed Web of Science ®Google Scholar
• Tsigkaropoulou E, Peppa M, Zompola C, et al. Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis. Gend Med 2012;9(1):56-60
   PubMed Web of Science ®Google Scholar
• Montejo AL, Majadas S, Rico-Villademoros F, et al. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med 2010;7(10):3404-13
   PubMed Web of Science ®Google Scholar
• Montejo AL, Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 2008;34(3):227-39
   PubMed Web of Science ®Google Scholar
• de Boer MK, Castelein S, Bous J, et al. The Antipsychotics and Sexual Functioning Questionnaire (ASFQ): preliminary evidence for reliability and validity. Schizophr Res 2013;150(2-3):410-15
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Iwamoto K, Sasada K, et al. Reliability and validity of a new sexual function questionnaire (Nagoya Sexual Function Questionnaire) for schizophrenic patients taking antipsychotics. Hum Psychopharmacol 2011;26(4-5):300-6
   PubMed Web of Science ®Google Scholar
• Shah SK. A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu Univ Med J (KUMJ) 2013;11(42):121-5
   PubMedGoogle Scholar
• Chaves KM, Serrano-Blanco A, Ribeiro SB, et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatr Q 2013;84(1):125-35
   PubMed Web of Science ®Google Scholar
• de Boer MK, Wiersma D, Bous J, et al. A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study). J Clin Psychopharmacol 2011;31(4):523-5
   PubMed Web of Science ®Google Scholar
• Fujii A, Yasui-Furukori N, Sugawara N, et al. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(2):288-93
   PubMed Web of Science ®Google Scholar
• Nagaraj AK, Pai NB, Rao S. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. Indian J Psychiatry 2009;51(4):265-71
   PubMedGoogle Scholar
• Perez V, Cañas F, Tafalla M, et al. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. Int Clin Psychopharmacol 2008;23(3):138-49
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164(3):415-27
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163(4):611-22
   PubMed Web of Science ®Google Scholar
• Knegtering H, Boks M, Blijd C, et al. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther 2006;32(4):315-26
   PubMed Web of Science ®Google Scholar
• Dossenbach M, Dyachkova Y, Pirildar S, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006;21(4):251-8
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• Olfson M, Uttaro T, Carson WH, et al. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry 2005;66(3):331-8
   PubMed Web of Science ®Google Scholar
• Dossenbach M, Erol A, el Mahfoud Kessaci M, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004;65(3):312-21
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60(7):681-90
   PubMed Web of Science ®Google Scholar
• Fortier P, Mottard JP, Trudel G, et al. Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults. Schizophr Bull 2003;29(3):559-72
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Pierre JM, Marder SR, et al. Sexual side effects of novel antipsychotic medications. Schizophr Res 2002;56(1-2):25-30
   PubMed Web of Science ®Google Scholar
• Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002;63(5):408-13
   PubMed Web of Science ®Google Scholar